NYSE:BHVNBiohaven Pharmaceutical Stock Price, Forecast & News

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BHVN stock has increased by 72.7% and is now trading at $68.15. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical.

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Biohaven Pharmaceutical.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($2.39) EPS for the quarter, topping the Zacks' consensus estimate of ($2.46) by $0.07. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.21 million. During the same period in the prior year, the business earned ($1.41) earnings per share. View Biohaven Pharmaceutical's earnings history.

11 equities research analysts have issued 1-year price objectives for Biohaven Pharmaceutical's stock. Their forecasts range from $41.00 to $100.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $66.90 in the next year. This suggests that the stock has a possible downside of 1.8%. View analysts' price targets for Biohaven Pharmaceutical.

Headlines about BHVN stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutBiohaven Pharmaceutical.

Some companies that are related to Biohaven Pharmaceutical include Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Horizon Therapeutics (HZNP), Mylan (MYL), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU), Crispr Therapeutics (CRSP), Biopharmx (BPMX), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Netflix (NFLX).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital International Investors (10.26%), BlackRock Inc. (5.61%), Wellington Management Group LLP (5.33%), Capital World Investors (3.75%), State Street Corp (3.38%) and Eventide Asset Management LLC (3.05%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical.

BHVN stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Nuveen Asset Management LLC, Pictet Asset Management Ltd., Two Sigma Investments LP, Two Sigma Advisers LP, Spark Investment Management LLC, Alliancebernstein L.P., and Rafferty Asset Management LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Elyse Stock, Eric Aguiar, John W Childs, Kimberly Gentile, and Robert Berman. View insider buying and selling activity for Biohaven Pharmaceutical.

BHVN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Capital World Investors, BlackRock Inc., Wells Fargo & Company MN, NWI Management LP, Foresite Capital Management IV LLC, and Eventide Asset Management LLC. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BHVN stock can currently be purchased for approximately $68.15.

Biohaven Pharmaceutical has a market capitalization of $3.99 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.